Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L.

Cancers (Basel). 2019 Feb 21;11(2). pii: E252. doi: 10.3390/cancers11020252. Review.

2.

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Asslaber D, Wacht N, Leisch M, Qi Y, Maeding N, Hufnagl C, Jansko B, Zaborsky N, Villunger A, Hartmann TN, Greil R, Egle A.

Clin Cancer Res. 2019 Mar 15;25(6):1901-1912. doi: 10.1158/1078-0432.CCR-18-1548. Epub 2018 Nov 28.

PMID:
30487125
3.

Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.

Leisch M, Egle A, Greil R.

Future Oncol. 2019 Jan;15(2):109-120. doi: 10.2217/fon-2018-0492. Epub 2018 Aug 16. Review.

PMID:
30111169
4.

Differences in Stem Cell Processing Lead to Distinct Secretomes Secretion-Implications for Differential Results of Previous Clinical Trials of Stem Cell Therapy for Myocardial Infarction.

Wernly B, Gonçalves I, Kiss A, Paar V, Mösenlechner T, Leisch M, Santer D, Motloch LJ, Klein KU, Tretter EV, Kretzschmar D, Podesser B, Jung C, Hoppe UC, Lichtenauer M.

Biotechnol J. 2017 Sep;12(9). doi: 10.1002/biot.201600732. Epub 2017 Aug 22.

PMID:
28731525
5.

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.

Wolff F, Leisch M, Greil R, Risch A, Pleyer L.

Cell Commun Signal. 2017 Mar 31;15(1):13. doi: 10.1186/s12964-017-0168-z. Review.

6.

Analysis of Ambient Influences Affecting Interleukin-6 Secretion in the Context of Clinical Trials of Stem Cell Therapy for Myocardial Infarction.

Edlinger C, Wernly B, Leisch M, Kammler J, Kypta A, Eder S, Jung C, Hoppe UC, Lichtenauer M.

Clin Lab. 2016;62(6):1061-8.

PMID:
27468568

Supplemental Content

Loading ...
Support Center